Page last updated: 2024-12-06

fluorexon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fluorexon: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65079
CHEMBL ID1973733
CHEBI ID51903
SCHEMBL ID23435
MeSH IDM0051100

Synonyms (58)

Synonym
c30h26n2o13
glycine, n,n'-[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3h),9'-[9h]xanthene]-2',7'-diyl)bis(methylene)]bis[n-(carboxymethyl)-
NCI60_002494
calcein
fluorescein,7'-bis[[bis(carboxymethyl)amino]methyl]-
glycine,n'-[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3h),9'-[9h]xanthene]-2',7'-diyl)bis(methylene)]bis[n-(carboxymethyl)-
acetic acid,6'-dihydroxy-2',7'-fluorandiyl)bis(methylenenitrilo)]tetra-
2,n-bis(carboxymethyl)aminomethylene]fluorescein
fluorexon
nsc298193
1461-15-0
nsc-298193
2,7-bis(n,n-bis(carboxymethyl)aminomethylene)fluorescein
oftasceine
oftasceinum
2,2',2'',2'''-[(3',6'-dihydroxy-3-oxo-3h-spiro[2-benzofuran-1,9'-xanthene]-2',7'-diyl)bis(methylenenitrilo)]tetraacetic acid
CHEBI:51903 ,
oftasceina
2',7'-bis((bis(carboxymethyl)amino)methyl)fluorescein
n,n'-(3',6'-dihydroxyspiro(phthalid-3,9'-xanthen)-2',7'-diyldimethyl)bis(iminodiessigsaeure)
fluorexone
2-[[7'-[[bis(carboxymethyl)amino]methyl]-3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-2'-yl]methyl-(carboxymethyl)amino]acetic acid
oftasceinum [inn-latin]
oftasccine
nsc 298193
v0ym2b16ts ,
einecs 215-957-1
fluorescein, 2',7'-bis((bis(carboxymethyl)amino)methyl)-
oftasceine [inn]
oftasceina [inn-spanish]
glycine, n,n'-((3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3h),9'-(9h)xanthene)-2',7'-diyl)bis(methylene))bis(n-(carboxymethyl)-
unii-v0ym2b16ts
FT-0623371
oftasceine [who-dd]
AKOS015903938
CHEMBL1973733
S5975
CCG-214792
SCHEMBL23435
2,2',2'',2'''-(((3',6'-dihydroxy-3-oxo-3h-spiro[isobenzofuran-1,9'-xanthene]-2',7'-diyl)bis(methylene))bis(azanetriyl))tetraacetic acid
CS-7704
mfcd00005049
bis[n,n-bis(carboxymethyl)aminomethyl]fluorescein
calcein for fluorometric determination of ca
sr-01000945252
SR-01000945252-1
154071-48-4
2,2,2,2-(((3,6-dihydroxy-3-oxo-3h-spiro[isobenzofuran-1,9-xanthene]-2,7-diyl)bis(methylene))bis(azanetriyl))tetraacetic acid
DB11184
HY-D0040
DEGAKNSWVGKMLS-UHFFFAOYSA-N
AS-35263
Q413006
fluorexonfluorexon
fluorescein complex
2-{[(7'-{[bis(carboxymethyl)amino]methyl}-3',6'-dihydroxy-3-oxo-3h-spiro[2-benzofuran-1,9'-xanthen]-2'-yl)methyl](carboxymethyl)amino}acetic acid
EN300-18528188
calcein, ultrapure grade

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Carvedilol and verapamil (10 micromol/L) reduced the LD50 (dose which results in the death of half the number of cells) of the Hs578T-Dox subline from 200 mg/L to approx."( Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Jonsson, O; Persson, M, 1999
)
0.3
" A modified 'amyloid cascade' hypothesis for Alzheimer's disease states that prefibrillar oligomers, also called amyloid-beta-derived diffusible ligands or globular oligomers, are the responsible toxic agent."( Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity.
Anderluh, G; Ceru, S; Gutierrez-Aguirre, I; Kopitar-Jerala, N; Macek, P; Rabzelj, S; Turk, V; Zerovnik, E, 2005
)
0.33
" The results show that bismuth nanoparticles are more toxic than most previously reported bismuth compounds."( In vitro cytotoxicity of surface modified bismuth nanoparticles.
Hossain, M; Luo, Y; Ma, L; Qiao, Y; Su, M; Wang, C, 2012
)
0.38
" Our data shows that the addition of rPrP to the assembling Aβ42 results in a shift in oligomer size distribution, decreasing the population of toxic tetramers and higher order oligomers and increasing the population of nontoxic (and possibly neuroprotective) monomers."( Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-β Oligomers Causing Cytotoxicity Inhibition.
Choi, JK; Surewicz, K; Surewicz, WK; Williams, TL, 2015
)
0.42
" Pituitary adenylate cyclase-activating polypeptide (PACAP) is an endogenous 38 amino-acid peptide with demonstrated protection against neuronal injury, trauma as well as various endogenous and exogenous toxic agents."( PACAP Protects Against Ethanol and Nicotine Toxicity in SH-SY5Y Cells: Implications for Drinking-Smoking Co-morbidity.
Csoka, AB; Getachew, B; Khundmiri, SJ; Manavalan, S; Manaye, KF; McKinley, R; Reglodi, D; Tamas, A; Tizabi, Y, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
"This study was undertaken to compare the effect of glucose injection on the pharmacokinetic behavior of a soluble dye in normal and tumoral tissues."( Noninvasive fluorescent study in situ and in real time of glucose effects on the pharmacokinetic of calcein.
Bégu, S; Devoisselle, JM; Mordon, S, 2002
)
0.31
" The physicochemical and pharmacokinetic properties of NOSC-modified DTX liposomes (NDLs) were evaluated compared with the conventional DTX liposomes (DLs) and commercial dosage form of DTX, Taxotere(®)."( N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics.
Qu, G; Wu, X; Yin, L; Zhang, C, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
"The in vitro antimicrobial activities of pannarin, a depsidone isolated from lichens, collected in several Southern regions of Chile (including Antarctica), was evaluated alone and in combination with five therapeutically available antibiotics, using checkerboard microdilution assay against methicillin-resistant clinical isolates strains of Staphylococcus aureus."( In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates.
Amicosante, G; Bellio, P; Brisdelli, F; Celenza, G; Garbarino, JA; Nicoletti, M; Perilli, M; Piovano, M; Segatore, B; Setacci, D, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" Formulation of Calcein (a water-soluble marker molecule, MW = 623), or SK&F 106760 (a water-soluble RGD peptide, MW = 634) in a w/o microemulsion having a composition of Captex 355/Capmul MCM/Tween 80/Aqueous (65/22/10/3, % w/w), resulted in significant bioavailability enhancement in rats relative to their aqueous formulations."( Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides.
Constantinides, PP; Ellens, H; Lancaster, C; Marcello, J; Marks, G; Scalart, JP; Smith, PL, 1994
)
0.29
" The absorption enhancing activity of w/o microemulsions incorporating these lipids was evaluated in the rat using Calcein (MW = 623) a water-soluble and poorly absorbed marker molecule."( Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation.
Constantinides, PP; Ellens, H; Owen, AB; Smith, PL; Sturgis, S; Welzel, G; Yiv, SH, 1996
)
0.29
" The large amount of calcein leakage induced by enhancers was consistent with an enhancement of bioavailability of verapamil and insulin following nasal administration (oleic acid < SG < Sit-G)."( The enhancing effect of soybean-derived sterylglucoside and beta-sitosterol beta-D-glucoside on nasal absorption in rabbits.
Kamata, K; Maitani, Y; Nagai, T; Nakamura, K; Suenaga, H; Takayama, K, 2000
)
0.31
" Modulation of intestinal Pgp dependent transport by GFJ may lead to changes in bioavailability of drugs that are substrates of Pgp itself, by affecting their presystemic clearance."( Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2.
Chieli, E; Donati, A; Romiti, N; Tramonti, G, 2004
)
0.32
" These findings could form the basis for the development of electroporation as a clinical tool to increase intestinal permeability and, thereby, increase the absorption of poorly absorbed drugs."( Increased permeability of intestinal epithelial monolayers mediated by electroporation.
Ghartey-Tagoe, EB; Morgan, JS; Neish, AS; Prausnitz, MR, 2005
)
0.33
"Multidrug resistance-associated protein 2 (MRP2) is associated with active drug efflux and may influence oral bioavailability of common classes of drugs."( Antibiotic exposure does not influence MRP2 functional expression in Caco-2 cells.
Hirst, BH; Moore, V; Prime-Chapman, H, 2005
)
0.33
"Stratum corneum composition and structure limit cutaneous bioavailability of pharmaceutical and cosmetical agents."( In vitro evaluation of the effect of electrotreatment on skin permeability.
Kalia, YN; Levy, JL; Marra, F; Santi, P, 2008
)
0.35
" Intestinal cells constitute a first barrier to mycotoxins exposure, since they express membrane ABC transporters that may affect the bioavailability of food xenobiotics."( ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites.
Delaforge, M; Lecoeur, S; Mazallon, M; Prouillac, C; Videmann, B, 2009
)
0.35
" Analyses of the absorption-enhancing effects of w/o/w emulsions on intestinal calcein absorption in rats showed that calcein bioavailability after intraduodenal (i."( Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability compound.
Koga, K; Takada, K; Takarada, N, 2010
)
0.36
" These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2."( Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010
)
0.36
"Food contains components that may either increase or decrease the bioavailability of a drug."( Effects of kaempferol on the mechanisms of drug resistance in the human glioblastoma cell line T98G.
Fukami, T; Furuishi, T; Hidaka, S; Nakatsuma, A; Suzuki, T; Tomono, K, 2010
)
0.36
" DFO antioxidant and iron binding properties were preserved and its bioavailability was increased upon CPP conjugation, which opens new therapeutic possibilities for neurodegenerative processes associated with brain iron overload."( Cell penetrating peptide (CPP)-conjugated desferrioxamine for enhanced neuroprotection: synthesis and in vitro evaluation.
Esposito, BP; Goswami, D; Machini, MT; Nomura, CS; Silvestre, DM, 2014
)
0.4
" Unfortunately, due to the low bioavailability and consequently low blood level, they cannot be used for cancer therapy."( Anthocyanidins but not anthocyanins inhibit P-glycoprotein-mediated calcein extrusion - possible implication for orally administered drugs.
Vrzal, R, 2016
)
0.43
"The simultaneous processes of lipid digestion and absorption together determine the oral bioavailability of drugs incorporated into lipid based drug delivery systems (LBDDS)."( Simultaneous lipolysis/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems.
Bauer-Brandl, A; Bibi, HA; Holm, R, 2017
)
0.46
" It can confer broad-spectrum multidrug resistance and can decrease the bioavailability of many important drugs."( Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Iram, SH; Peterson, BG; Sampson, A; Tan, KW, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The process of permeabilization proceeds as a pseudo first-order reaction, indicating that the toxin is active as a monomer; consistently no evidence for cooperativity has been found in a dose-response titration."( Escherichia coli hemolysin permeabilizes small unilamellar vesicles loaded with calcein by a single-hit mechanism.
Menestrina, G, 1988
)
0.27
"01), with a dose-response relationship for increases in Wb."( The response of rat tibiae to incremental bouts of mechanical loading: a quantum concept for bone formation.
Forwood, MR; Turner, CH,
)
0.13
" Quantitative dose-response values obtained from surviving cell fractions assayed by flow cytometry at 24 h following drug exposure demonstrated the utility of this assay for quantitating drug-induced cytotoxic effects on primary human AML cells in short-term culture."( Quantitative measurements of the efficacy of new anti-cancer agents on fresh human AML cells by using multivariate flow analysis.
Edelstein, MB; KuKuruga, MA; Media, JE; Nakeff, A; Valeriote, F, 1996
)
0.29
"Delivery of drugs through the skin and the buccal mucosa has been considered as an alternative to per oral dosing for those substances that are degraded in the gastro-intestinal tract, or are subject to first-pass metabolism in the liver."( Buccal mucosa in vitro experiments. I. Confocal imaging of vital staining and MTT assays for the determination of tissue viability.
Cullander, C; Imbert, D, 1999
)
0.3
" From dose-response curves with Sf9 membrane vesicles, glutathionylcurcumin conjugates appeared to be less potent inhibitors of MRP1 and MRP2 than their parent compound curcumin."( Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
Boersma, MG; Cnubben, NH; Rietjens, IM; Spenkelink, B; Usta, M; van Bladeren, PJ; van der Velde, AE; van Zanden, JJ; Wortelboer, HM, 2003
)
0.32
" These data demonstrated that full Runx2 gene dosage is required for maintaining normal function of osteoblasts in mechanical unloading or nonphysiological condition."( Runx2 is a target of mechanical unloading to alter osteoblastic activity and bone formation in vivo.
Ezura, Y; Komori, T; Nakashima, K; Noda, M; Salingcarnboriboon, R; Tsuji, K, 2006
)
0.33
"The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis."( Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006
)
0.33
" The physicochemical and pharmacokinetic properties of NOSC-modified DTX liposomes (NDLs) were evaluated compared with the conventional DTX liposomes (DLs) and commercial dosage form of DTX, Taxotere(®)."( N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics.
Qu, G; Wu, X; Yin, L; Zhang, C, 2012
)
0.38
" In recent years, photo-responsive nanoparticles (NPs) have received considerable attention because of their potentials in providing spatial, temporal, and dosage control over the drug release."( Non-invasive controlled release from gold nanoparticle integrated photo-responsive liposomes through pulse laser induced microbubble cavitation.
Gao, Y; Liu, Q; Liu, Y; Mathiyazhakan, M; Ohl, CD; Tam, KC; Xu, C; Yang, Y; Zhu, C, 2015
)
0.42
"Photo-responsive nanoparticles (NPs) have received considerable attention because of their potential in providing spatial, temporal, and dosage control over the drug release."( Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation.
Chan, W; Mathiyazhakan, M; Ohl, CD; Xu, C, 2016
)
0.43
"Transdermal administration of drugs represents an excellent alternative to conventional pharmaceutical dosage forms."( A Novel Chemical Enhancer Approach for Transdermal Drug Delivery with C
Hijikuro, I; Kadhum, WR; Sekiguchi, S; Sugibayashi, K; Todo, H, 2017
)
0.46
" However, both modi require a very accurate real-time dosing control in order to avoid extended retinal disintegration in this power range."( Investigations on Retinal Pigment Epithelial Damage at Laser Irradiation in the Lower Microsecond Time Regime.
Birngruber, R; Brinkmann, R; Grisanti, S; Kleingarn, P; Miura, Y; Seifert, E; Sonntag, SR; Theisen-Kunde, D, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fluorochromeA fluorescent dye used to stain biological specimens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
xanthene dyeA dye derived by condensation of phthalic anhydride with resorcinol (and derivatives) or m-aminophenol (and derivatives).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 1 Homo sapiens (human)Km268.00000.73002.65505.0000AID679991
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (23)

Processvia Protein(s)Taxonomy
leukotriene metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
response to xenobiotic stimulusMultidrug resistance-associated protein 1 Homo sapiens (human)
cobalamin transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid biosynthetic processMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to oxidative stressMultidrug resistance-associated protein 1 Homo sapiens (human)
heme catabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 1 Homo sapiens (human)
phospholipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
positive regulation of inflammatory responseMultidrug resistance-associated protein 1 Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cell chemotaxisMultidrug resistance-associated protein 1 Homo sapiens (human)
transepithelial transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cyclic nucleotide transportMultidrug resistance-associated protein 1 Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to amyloid-betaMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
ATP bindingMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type vitamin B12 transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basal plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
lateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular exosomeMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID681291TP_TRANSPORTER: inhibition of DNP-SG uptake (DNP-SG: 0.01 uM, Calcein: 500 uM) in membrane vesicles from GLC4/ADR cells1997Biochimica et biophysica acta, May-22, Volume: 1326, Issue:1
Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport.
AID1669222Inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake at 30 to 300 uM incubated for 15 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID679991TP_TRANSPORTER: efflux in GLC4/ADR cells1998Biochemistry, Feb-24, Volume: 37, Issue:8
Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,399)

TimeframeStudies, This Drug (%)All Drugs %
pre-199068 (4.86)18.7374
1990's258 (18.44)18.2507
2000's524 (37.46)29.6817
2010's488 (34.88)24.3611
2020's61 (4.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.55 (24.57)
Research Supply Index7.28 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.28%)5.53%
Reviews10 (0.69%)6.00%
Case Studies2 (0.14%)4.05%
Observational0 (0.00%)0.25%
Other1,436 (98.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]